bioMérieux – Third-Quarter 2019 Business Review

22 October, 2019

  • Organic growth of 6.8% at constant exchange rates and scope of consolidation over the first nine months of the year:
    • €1,928 million in sales
    • Up 10.3% as reported
  • Acceleration of organic growth in sales to reach 9.6% in the third quarter driven bystrong momentum across all Regions
  • 2019 targets:
    • Organic growth in sales of around 7%
    • Contributive operating income before non-recurring items of between €385 million and €400 million

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux performed well in the third quarter of 2019. Fast-paced growth continued, driven primarily by a solid increase in reagent sales that reached 8% growth for the first nine months of the year. Given our business outlook and a high basis of comparison in the fourth quarter, organic growth in sales should come in at around 7.0% for the full year and our target margin is confirmed.


 

Pioneering Diagnostics